Millie Fell, MD
Ophthalmology · Brooklyn, NYNPI 1780607192
Payments from drug & device makers
Across 126 payments — averaging $23.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$435
- Regeneron Healthcare Solutions, Inc.$389
- Mallinckrodt Hospital Products Inc.$265
- Sun Pharmaceutical Industries Inc.$256
- AbbVie$215
- Tarsus Pharmaceuticals, Inc.$196
- plus $1K from 19 others
What the payments were for
- Food & beverage$2,89599%
- Gifts$191%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 20 | $435 |
| Regeneron Healthcare Solutions, Inc. | 13 | $389 |
| Mallinckrodt Hospital Products Inc. | 11 | $265 |
| Sun Pharmaceutical Industries Inc. | 11 | $256 |
| AbbVie(2 entities) | 12 | $215 |
| Tarsus Pharmaceuticals, Inc. | 7 | $196 |
| Bausch & Lomb Americas Inc. | 6 | $122 |
| Thea Pharma Inc. | 6 | $120 |
| Dompe US, Inc. | 4 | $109 |
| Oyster Point Pharma, Inc. | 5 | $92 |
| Apellis Pharmaceuticals, Inc. | 3 | $89 |
| Aerie Pharmaceuticals, Inc. | 4 | $89 |
| Genentech USA, Inc. | 3 | $70 |
| Akorn Operating Company LLC | 3 | $63 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 3 | $54 |
| Biotissue Holdings Inc. | 2 | $48 |
| Eyevance Pharmaceuticals LLC | 2 | $48 |
| Harrow Eye, LLC | 2 | $47 |
| Kala Pharmaceuticals, Inc. | 2 | $45 |
| Novartis | 2 | $38 |
| Sight Sciences, Inc. | 1 | $30 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $28 |
| Rayner Intraocular Lenses Limited | 1 | $25 |
| Amgen | 1 | $21 |
| Carl Zeiss Meditec AG | 1 | $19 |
How this compares
$2,914 in reported general payments places this provider in the 65th percentile of 1,587 ophthalmology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 57 | $61,063 |
| LumiganBimatoprost | 90 | $50,399 |
| CombiganBrimonidine Tartrate/Timolol | 38 | $21,778 |
| ProlensaBromfenac Sodium | 55 | $21,268 |
| Prednisolone Acetate | 236 | $12,704 |
| RhopressaNetarsudil Mesylate | 24 | $11,625 |
| Brimonidine Tartrate | 103 | $11,378 |
| Cyclosporine | 19 | $11,237 |
| XiidraLifitegrast | 12 | $10,861 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 43 | $8,624 |
| ZerviateCetirizine Hcl | 18 | $8,428 |
| Ketorolac Tromethamine | 269 | $8,401 |
| RocklatanNetarsudil Mesylat/Latanoprost | 21 | $7,585 |
| Timolol Maleate | 142 | $7,134 |
| IlevroNepafenac | 13 | $5,654 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan | $215 | $133,240185 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa | $54 | $21,26855 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $89 | $19,21045 claims |
| Bausch & Lomb Americas Inc.Xiidra | $122 | $10,86112 claims |
| AlconSimbrinza | $435 | $8,62443 claims |
| Eyevance Pharmaceuticals LLCZerviate | $48 | $8,42818 claims |
| NovartisIlevro | $38 | $5,65413 claims |
| Thea Pharma Inc.Iyuzeh | $120 | $3,70913 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,587 ophthalmology providers in New York.
Other ophthalmology in Brooklyn
- David RubaltelliBrooklyn$8.9M
- Irene GladsteinBrooklyn$250K
- Douglas JabsNew York$24.3M
- Philip FerroneGreat Neck$5.8M
- Eric DonnenfeldGarden City$2.6M
- Nathan RadcliffeNew York$2.4M
- Glenn StollerRockville Centre$2.1M
- Richard SpaideNew York$1.7M
- Paul HartmanRochester$1.6M
- Jason SlakterNew York$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.